13hode ethanolamide

13(S)HODE Ethanolamide is a biochemical used to inhibit the adhesion of tumor cells

(±)13-HODE is one of the two racemic monohydroxy fatty acids resulting from the non-enzymatic oxidation of linoleic acid. It is the principle hydroxylated fatty acid in human psoriatic skin scales, with a mean concentration of 17 ng/mg.[1]

13(R)-HODE cholesteryl ester was originally extracted from atherosclerotic lesions. It remains uncertain whether the oxidized fatty acid portion of the molecule results from enzymatic lipoxygenation or from random lipid peroxidation. 13(R)-HODE cholesteryl ester can be used as a standard for analysis of chiral HODE cholesteryl esters.

(±)13-HODE cholesteryl ester, initially extracted from atherosclerotic lesions, is produced via Cu2+-catalyzed oxidation of LDL. Subsequent studies revealed that 15-LO from rabbit reticulocytes and human monocytes could metabolize cholesteryl linoleate (a major LDL component) to 13-HODE cholesteryl ester.

13(R)-HODE is the opposite enantiomer of 13(S)-HODE produced when linoleic acid is incubated with soybean lipoxygenase. Its presence in supernatants and membranes of cultured bovine endothelial cells has been attributed to COX metabolism. 13(R)-HODE is a weak (IC50 = 2.7 μM) inhibitor of U-46619-induced platelet aggregation.

13(S)-HODE is the lipoxygenase metabolite of linoleic acid. 13(S)-HODE modulates the platelet-activating factor, leukotriene B4, and formyl-Met-Leu-Phe-induced calcium influx in human polymorphonuclear leukocytes. The mechanism by which 13(S)-HODE elicits its inhibitory effect is still unclear. The use of biotinylated 15(S)-HETE as a probe for detecting binding proteins and/or receptors that specifically bind 15(S)-HETE provides a basis for similar use of 13(S)-HODE-biotin.